Qsymia set for US launch and Belviq waits out classification as Contrave CV trial speeds ahead
This article was originally published in Scrip
Executive Summary
Orexigen Therapeutics reported on 5 September that it has achieved faster than anticipated patient enrolment in the cardiovascular outcomes trial (CVOT) requested by the US FDA earlier this year for the San Diego-based company's Contrave (naltrexone SR/bupropion SR), which could indicate strong patient demand for weight loss drugs generally, according to at least one equity analyst that follows competitors in the obesity market.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.